



Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America

Julio Alonso-Padilla, Nuria Cortés-Serra, María Jesús Pinazo, María Elena Bottazzi, Marcelo Abril, Fabiana Barreira, Sergio Sosa-Estani, Peter Jay Hotez & Joaquim Gascón

To cite this article: Julio Alonso-Padilla, Nuria Cortés-Serra, María Jesús Pinazo, María Elena Bottazzi, Marcelo Abril, Fabiana Barreira, Sergio Sosa-Estani, Peter Jay Hotez & Joaquim Gascón (2019): Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America, Expert Review of Anti-infective Therapy, DOI: [10.1080/14787210.2019.1577731](https://doi.org/10.1080/14787210.2019.1577731)

To link to this article: <https://doi.org/10.1080/14787210.2019.1577731>



Accepted author version posted online: 04 Feb 2019.
Published online: 13 Feb 2019.



Submit your article to this journal [↗](#)



Article views: 48





View Crossmark data [↗](#)

PERSPECTIVE



Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America

Julio Alonso-Padilla ^a, Nuria Cortés-Serra^a, María Jesús Pinazo^a, María Elena Bottazzi^{b,c,d}, Marcelo Abril^e, Fabiana Barreira^f, Sergio Sosa-Estani^{g,h}, Peter Jay Hotez ^{b,c,d} and Joaquim Gascón^a

^aISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; ^bNational School of Tropical Medicine; Pediatrics and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA; ^cTexas Children's Hospital Center for Vaccine Development, Houston, TX, USA; ^dDepartment of Biology, Baylor University, Waco, TX, USA; ^eFundación Mundo Sano, Buenos Aires, Argentina; ^fFabiana Barreira, DNDi, Rio de Janeiro, Brazil; ^gCentro de Investigación de Epidemiología y Salud Pública (CIESP-IECS), CONICET, Buenos Aires, Argentina; ^hChagas disease Program, DNDi, Rio de Janeiro, Brazil

ABSTRACT

Introduction: Chagas disease, caused by infection with the parasite *Trypanosoma cruzi*, represents a huge public health problem in the Americas, where millions of people are affected. Despite the availability of two drugs against the infection (benznidazole and nifurtimox), multiple factors impede their effective usage: (1) gaps in patient and healthcare provider awareness; (2) lack of access to diagnosis; (3) drug toxicity and absence of treatment algorithms to address adverse effects; (4) failures in drug supply and distribution; and (5) inconsistent drug efficacy against the symptomatic chronic stage.

Areas covered: We review new approaches and technologies to enhance access to diagnosis and treatment to reduce the disease burden. We also provide an updated picture of recently published and ongoing anti-*T. cruzi* drug clinical trials. Although there has been progress improving the research and development (R&D) landscape, it is unclear whether any new treatments will emerge soon. Literature search methodologies included multiple queries to public databases and the use of own-built libraries.

Expert opinion: Besides R&D, there is a major need to continue awareness and advocacy efforts by patient associations, local and national governments, and international agencies. Overall, health systems strengthening is essential to ensure vector control commitments, as well as patient access to diagnosis and treatment.

ARTICLE HISTORY

Received 23 November 2018
Accepted 30 January 2019

KEYWORDS

Chagas disease;
comprehensive care;
diagnosis; treatment;
pharmacovigilance

1. Introduction

Chagas disease, or American trypanosomiasis, is caused by the protozoan parasite *Trypanosoma cruzi* (*T. cruzi*) and remains one of the most deadly and intractable neglected tropical diseases (NTDs) in the Western Hemisphere [1]. Updated information from the Global Burden of Disease Study (GBD) 2016 indicates that 7,100 people die from Chagas disease annually, roughly the same number of Chagas disease-related deaths that occurred a decade previously [2]. However, these numbers may represent highly conservative estimates with further findings that as many as 200,000 people living with *T. cruzi* infection may die over the next five years [3]. The GBD 2016 also finds that 7.2 million now live with Chagas disease, while 180,000 new *T. cruzi* infections occur annually [4].

Beyond its horrific disease burden and contribution to infectious disease mortality, there is a profoundly disturbing social impact dimension to Chagas disease related to its importance as a health disparity. Today, tens of thousands of people face a death sentence from their *T. cruzi* infection due to Chagasic cardiomyopathy, which could be prevented by timely access to diagnosis and anti-parasitic treatment with one of two nitroheterocyclic drugs – benznidazole (BNZ) and nifurtimox (NFX). Fueling a growing outrage from the global

health community is the finding that approximately 90% of the people infected with *T. cruzi* now live in Latin America's three wealthiest economies: Argentina, Brazil, and Mexico. In the United States of America (USA), the richest country of the continent and main destiny of those looking for a better future, there are at least 200,000 immigrants from Latin America living with Chagas disease with limited or no access to treatment [5,6]. Furthermore, in Europe, there are around 120,000 immigrants from Latin America living with Chagas diseases with a disparity of situations regarding access to care and treatment [7,8].

The overwhelming majority of Chagas disease sufferers are unable to gain access to diagnosis and treatment, not only because they are poor, but also because governmental leaders are either uninformed or uninterested. For example, it is noteworthy that the registration of BNZ for the treatment of pediatric Chagas disease in the USA has not been approved until very recently [9]. Documenting such assertions is not easy and seeking solutions to diagnosis and treatment access are not straightforward endeavors. In Mexico, for example, there are almost one million people living with Chagas disease, although even that number may represent a profound underestimate [10]. Yet, only 3,013 *T. cruzi* infection cases were registered nationally between the years 2007 and 2011, less

Article highlights

- Chagas disease is a neglected disease caused by the parasite *Trypanosoma cruzi* (*T. cruzi*) that affects millions of people in the Americas. Traditionally stigmatizing, hidden by society and ignored by governments, thanks to researchers, patients' associations and several other actors who have raised awareness and promoted education on the disease, there has been a shift towards improved diagnosis, treatment, and control in recent decades.
- There are highly sensitive and specific diagnostics for the acute and the chronic stages of the infection. However, they are not widely implemented in areas distant from reference laboratories due to logistical issues and the lack of equipped facilities and trained personnel. Thus, more practical algorithms should be used to provide point-of-care diagnostics.
- Two drugs are available to treat the infection: benznidazole and nifurtimox. Both are highly efficacious in newborns, but access to treatment generally occurs at the chronic stage when symptomatology arises. Due to their frequent adverse side effects, pharmacovigilance programs to report drug toxicities and a better management of these in primary care establishments must be implemented to ensure tighter adherence to medication.
- Stronger involvement of public health institutions and authorities is fundamental to progress in the disease control and its adequate management. The establishment of counter-reference circuits integrated in national health services plans will be fundamental to catalyze and scale up the attention and care of Chagas disease patients in endemic and non-endemic settings.
- Some regions have made great progresses in the control of vector-related transmission, but there are yet many where vector transmission is active. Increased cooperation between vector control programs and medical programs must be put on place to maximize their impact in public health.
- The role of patients' associations must remain active and press on other stakeholders so as to keep up Chagas disease visibility. Patients' organizations are at the frontline to demand attention from the responsible authorities, ensure adequate medical care, and ask for returns on investment from R&D.
- In line with the disease awareness shift, the clinical research landscape has also changed for the better. There are several clinical studies ongoing and their results are expected to improve diagnosis and treatment policies.

than 1% of the actual number of people affected with the disease [11]. A similar situation has been documented for the USA [12] and also likely holds true across the Americas. We are facing a situation where less than 1% of Chagas disease patients have access to timely and appropriate diagnosis and treatment [13,14].

Limiting access to essential medicines also has important implications for new research and development (R&D) related to therapeutic interventions. An exciting development on this front is a new orally bioavailable nitroheterocyclic drug, fexinidazole, which is also effective against human African trypanosomiasis [15]. Additional drugs are also under development, as well as there are Chagas disease vaccine (immunotherapeutic) candidates at pre-clinical stage [16]. In this respect, the Texas Children's Hospital Center for Vaccine Development, a Product Development Partnership, is exploring an approach that links therapeutic vaccination to pharmacotherapy [17]. However, any R&D successes must still face a formidable gauntlet of truncated and mostly failed global access mechanisms. Similar forces are a barrier for access to new and innovative diagnostics [18].

Here we report on some of the major hurdles that currently block access to the diagnosis and treatment of Chagas disease.

The problems include both scientific and socioeconomic obstacles. This paper aims to elucidate the challenges they pose and offer solutions.

2. The need of more practical and useful diagnostics

The poor access rate to Chagas disease therapeutic treatments has its roots in the clinical nature of the disease itself and its silent progression from the mostly asymptomatic acute stage into the symptomatic chronic one [1]. Unfortunately, biomarkers of disease progression and standardized tools to determine early response-to-treatment are yet unavailable, which greatly complicates the prognosis and follow-up of patients [19].

Treatment administration, as in any other disease, needs to be preceded by an adequate diagnosis. In the case of Chagas disease, when a clinical diagnosis is achieved, tissue disruptions might already be too advanced for a chemotherapeutic intervention. Therefore, parasite detection must be sought before the onset of overt symptomatology. In the acute infection stage, for instance, upon congenital transmission of the parasite, parasitemia can be detected by direct microscopic observation [1]. However, this stage is short lasting and generally goes unnoticed as there are often no symptoms at all. Approximately 30% of these infected individuals will progress to evidence either Chagasic cardiac or gastrointestinal disease. Those without clinical evidence of disease are said to be at the indeterminate stage, whereas those with cardiac or gastrointestinal involvement are at the determinate stage. The development of life-threatening heart and/or digestive tract disruptions, which can be massive and are called mega-syndromes, occurs in the long-lasting chronic stage [1].

In both indeterminate and determinate Chagasic patients, parasitemia is typically low and intermittent and the diagnosis of the infection is made by means of indirect serological tests, like enzyme-linked immunosorbent assays (ELISAs). This is possible because high levels of parasite-specific immunoglobulins are produced upon *T. cruzi* infection (Figure 1). Anti-*T. cruzi* type G immunoglobulins (IgGs) levels remain above detection thresholds for many years, which is advantageous for the serological diagnosis of the infection (Figure 1). However, it turns out to be an inconvenience for a serology-based assessment of drug responses as it can take several years for them to revert after the administration of treatment [20]. Another issue to take into account in the diagnosis of the infection is the wide genetic variability of the parasite, which encompasses seven different genotypes grouped in Discrete Typing Units (DTUs) [21]. A role of the parasite and host genetics interplay has been suggested in relation to the sensibility to treatment of the distinct isolates, the pathological signatures of the infection, and also in the anti-*T. cruzi* immune response [21].

Some studies indicate that treatment interventions while patients are in the indeterminate or early determinate stages are critically important in order to prevent advanced disease progression. In contrast, from the multi-centered BENEFIT trial to evaluate BNZ efficacy it was found that patients with significant cardiac involvement progressed to advanced disease or even died despite receiving specific anti-parasitic chemotherapy [3,22]. Currently, several classifications (for instance, AHCC,




Figure 1. Timescale scheme of Chagas disease diagnosis and clinical status progression.

or Kuschner's modified) are in place to differentiate people with early-stage (grades A-B or 0-I, respectively) versus late stage (grades C-D or II-III, respectively) cardiac disease. Treatment of patients with grades C-D or II-III was not encouraged previously [1], a finding that appears to hold up in light of the recent BENEFIT findings. These findings highlight the importance of identifying both indeterminate patients with Chagas disease, and possibly those with AHCC grades A-B or modified Kuschner grades 0-I too, since they might be successfully treated with antiparasitic therapy if they were captured during population-wide screening campaigns [3]. In this way, it would be possible to identify and treat chronically infected people before they develop the symptomatology. Women at child-bearing age and newborns should receive special attention because the treatment of mothers-to-be has been shown to largely reduce the transmission rate [23–26], and the efficacy and tolerability of current drugs by infected newborns is ~100% [1]. Moreover, health economics studies evaluating Chagas disease surveillance in endemic and non-endemic settings indicate that widespread screening would be highly cost-effective [27–30]. In the two disease scenarios studied, congenital (acute infection transmitted by chronically infected mothers) and indeterminate (chronic asymptomatic stage), mass screening would save health costs even at *T. cruzi* prevalence rates as low as 0.9% or 0.05%, respectively (in fact estimated in a non-endemic setting) [27,29].

Due to the very limited resources available for Chagas disease management, and echoing the answers provided by Latin American experts enquired by Picado et al. [18], efforts should focus on making widely available point-of-care (PoC) tests to diagnose congenital transmission and indeterminate chronic patients [18]. However, if we want to enable generalized Chagas disease diagnosis, there is an urgent need of more practical diagnostic reagents and kits. Availability of easy-to-use tools for the early assessment of treatment response would also

be highly valuable to promote and support the administration of drugs against the infection. In this regards, there are some biomarkers under research [19], but the evaluation of anti-*T. cruzi* drug responses yet relies on the molecular amplification of the parasite DNA from periphery blood obtained at distinct times post-treatment. Unfortunately, its associated high costs and technical requirements restrict its use to the context of well-funded clinical trials [31].

2.1. Current Chagas disease diagnostics are impractical in many regions

Regarding acute stage diagnostics, classical parasitological methods (micromethod, hemoculture and xenodiagnoses) are microscopy-based and rely on finding motile trypomastigotes in blood, thus they provide both low sensitivity and specificity. Due to their poor performance, current algorithm to diagnose congenital transmission involves two micro-methods (at birth and at 1–2 months of age), and a further confirmatory serological test once mother-derived IgGs have waned at infant's 8–12 months of age [32]. This has two major drawbacks: a very high loss-to-treatment risk during pediatric follow-up, and the reduction of drug efficacies the longer the treatment is delayed [32]. Molecular amplification of *T. cruzi* DNA, either by conventional polymerase chain reaction (PCR) or by quantitative PCR (qPCR), has been shown to be more sensitive and specific than classical parasitological techniques [20]. Several laboratories have worked on the standardization of the techniques so that their outcomes can be comparable and implemented in clinic-based laboratories [20]. But molecular biology laboratories are expensive to mount and maintain, plus they require highly trained personnel to run them. Therefore, despite its very good performance, molecular detection is not generally used beyond regional or national reference laboratories in endemic regions.

In relation to the current chronic stage diagnostics, conventional serological tests (like ELISAs, indirect immunofluorescence or indirect hemagglutination assays) use serum or plasma samples that entail venous extraction and blood segregation by centrifugation, and they require a cold chain to preserve the test reagents and the samples. Moreover, due to the parasite's antigenic diversity, the advice from the World Health Organization (WHO) is to run two tests based on distinct antigenic sets and if their outcomes are not concurrent, to employ a third technique [14]. This algorithm is costly, and it requires equipment and resources that are usually not available in many laboratories of endemic regions. Furthermore, the turnaround of results to the patient can take several weeks, which involves a high risk of losing contact with the patient for treatment.

2.2. What solutions could be implemented?

Fortunately, recent technological advancements are procuring solutions to overcome the limitations mentioned above. We will outline them separately considering first those for the diagnosis of acute stage and then those for the diagnosis of chronic Chagas disease.

In recent years, isothermal amplification methods that do not require expensive equipment (such as thermocyclers or gel visualization systems) and are easier to perform than PCR assays have been developed for the molecular detection of several NTDs [20]. At present, a prototype of Loop isothermal AMPLification for *T. cruzi*-DNA (LAMP, Eiken Co., Japan) has been tested with clinical samples and shown to have a comparable performance to qPCR with blood-EDTA samples [33]. Another LAMP test developed in house by Rivero et al. [34] has also been shown to provide a comparable performance to current congenital transmission algorithm. LAMP is based on a microbiological DNA polymerase that works at a constant temperature of 65°C for 45 min with a set of 4 to 6 complex primer sequences to provide a highly sensitive and specific amplification [35]. LAMP readout is qualitative, and the results can be naked eye visualized in a short time given a probe (e.g. calcein) is added to the reaction mix. If a digital fluorimeter is used (e.g. Genie III), the reading can even be semi-quantitative [33]. Notably, in Eiken's *T. cruzi*-LAMP prototype, reagents are provided dried out in the lids of the reaction tubes which allow a ready-to-use format and a much desirable room temperature storage [33]. More recently, a Recombinase Polymerase Assay (RPA), which even requires a lower amplification temperature and shorter amplification time (40°C for 30 min) than LAMP, has been tested with samples from naturally *T. cruzi*-infected dogs [36]. This RPA has been coupled to a lateral flow strip for results reading, and it was shown to provide excellent agreement with qPCR results [36]. There are RPAs for the detection of other NTDs [37,38], so it could also be very useful for Chagas disease molecular diagnosis.

For the serological detection of *T. cruzi*-specific IgGs, rapid diagnostic tests (RDTs) have been commercially developed during the last two decades [39,40]. RDTs have clear advantages over conventional serology, as they can be stored at room temperature, use a very small volume (5–25 µl) of finger

pricked whole blood, have an easy-to-run and read cassette format, and provide a fast turnaround of results (less than 45 min) [40]. Several studies now support their implementation as they have been extensively validated against conventional tests [41–43]. For instance, an RDT is currently used for primary screening of chronic Chagas disease in Bolivia [41]. Nonetheless, following the WHO guidelines of two-tests concordance, confirmation of that RDT primary result must yet be made with a conventional serological test [14]. Such recommendations reduce the advantages of RDTs.

With the aim to fully exploit RDTs advantages and to determine whether they can substitute conventional tests, combinatory use of two RDTs has been proposed [41]. So far, in a proof-of-concept study performed in the city of Sucre (Bolivia), perfect agreement between the two RDTs used was observed, and their sensitivity and specificity in comparison with three conventional tests was 100% and 99.3%, respectively [41]. However, despite a promising performance in Bolivia [41,43], RDTs have not worked so well when they have been used in other geographical regions [44]. This might be related to the high prevalence of the disease in Bolivia, which may allow an easier detection, or to the fact that the parasite strains used to produce the RDTs antigens are those circulating in Bolivia. In any case, until more results from different epidemiological areas are available, preliminary geographical testing of the RDTs performance has been proposed before using them in a particular region [44]. In view of the advantages they bring versus conventional tests, RDTs implementation for Chagas disease surveillance should be evaluated at larger scales.

3. Treatment of Chagas disease, and related issues

3.1. Drug regimens

Evidence about the benefits of Chagas disease treatment, together with a growing understanding of the pathogenesis of the disease, led to the paradigm that all *T. cruzi*-seropositive patients should receive treatment with anti-*T. cruzi* drugs [45]. The recently published results of the SaMi-Trop cohort study further reaffirm this statement as they demonstrate a beneficial effect of BNZ in reducing the cardiac clinical progression of chronic Chagas disease patients [46]. Therefore, anti-trypanosomatid treatment should be provided to all *T. cruzi*-infected people who do not present with advanced cardiac complications (Kuschnir's modified grades II-III), as by then clinical manifestations might not be improved [47]. Nonetheless, access to treatment confronts important limitations. BNZ and NFX, the only drugs available for *T. cruzi* infection, exhibit reduced efficacy during the chronic stage of the disease, and require a long period of administration which causes frequent unwanted drug-related adverse reactions (ADRs) [48–50]. Furthermore, variable drug susceptibility has been already described among distinct *T. cruzi* strains [51]. In this context, there is an urgent need for more efficacious and safer drugs or drugs' regimens, in particular for the treatment of the chronic stage of the infection.

One alternative is the reduction of the BNZ dose and/or schedule in order to improve safety and adherence to treatment; an approach that is supported by clinical and

experimental data. In a pilot study, Álvarez et al. [52] assessed a new scheme of BNZ administration in a small cohort of chronic Chagas disease patients treated with intermittent doses of BNZ at 5 mg/kg/day every 5 days for a total of 60 days. The study showed a satisfactory safety profile, with low rates of treatment suspension and treatment failure [52]. An experimental study using a mouse model of chronic *T. cruzi* infection had demonstrated before the effectiveness of an intermittent scheme of BNZ administered every 5 days for 40 days [53]. These findings support the intermittent administration of BNZ as a new dosage schedule, but further research to confirm its efficacy by long-term assessment of larger cohorts is needed. Another therapeutic option under investigation is the co-administration of an immunotherapeutic (vaccine) treatment and BNZ. In this regards, enhancement of a *T. cruzi*-specific immune response has been shown to contribute to support the efficacy of reduced BNZ dosages in a mouse model of acute *T. cruzi* infection [17].

3.2. Drug availability

Drug access is still a huge problem in some endemic areas [13]. BNZ, generally the first line therapy for Chagas disease, is part of the WHO List of Essential Medicines [54]. It was produced for more than 40 years by Roche (Basilea, Switzerland), which transferred its production rights to Laboratório Farmacêutico de Pernambuco (LAFEPE), a Brazilian public enterprise, at the end of the twentieth century. Sadly, BNZ production and distribution by LAFEPE failed to meet expectations in terms of meeting supply and demand requirements and in 2011 an important shortage of the drug occurred. It lasted 1.5 years and left thousands of patients without treatment worldwide [13,55]. This fact led to the development of a Private–Public Partnership in Argentina involving Maprimed (for the synthesis of the drug) and ELEA (for its development and production), to promote equitable availability of BNZ [56]. Since 2012, this Argentinian Partnership has worked to guarantee the availability of the drug, distributing BNZ to the countries in the region [56]. NFX, which is mostly used as the second line treatment option, is produced and donated by the pharmaceutical company Bayer and distributed through the Pan-American Health Organization (PAHO) Strategic Fund [57]. Recently, a NFX produced by Gador has also been registered in Argentina. Definitely, a regular, safe and accessible production of these two anti-parasitic drugs is necessary to guarantee the treatment to diagnosed patients, and the access to drugs has to be ensured in adequate quantity, quality, location, and timing.

3.3. Pharmacovigilance

A major limitation of current Chagas disease treatments is the onset of Adverse Drug Reactions (ADRs), which may lead to poor medication adherence, and cause thereby therapeutic failure or ineffective treatment [48–50]. ADRs are defined as ‘an appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product,

which predicts hazard from future administration and warrants prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the product’ [58]. The most commonly observed ADRs related to BNZ are headache, dermatological manifestations, and gastrointestinal symptoms [49,50]. Concerning NFX, digestive symptoms are the most frequent [48]. Nevertheless, with an adequate clinical management, most of the patients are able to finish treatment in the advent of ADRs [49]. Close medical follow-up, adequate monitoring of ADRs and implementation of robust pharmacovigilance systems are essential factors to avoid patient abandonment and achieve therapeutic success.

Although pharmacovigilance is crucial, it is still a neglected area. Latin-American countries are making important efforts to report ADRs, but these activities are recent and need reinforcement [59,60]. Results of an unpublished study conducted by Cortes-Serra et al. in Bolivia during 2016 indicate that 35.4% of the total patients treated for Chagas disease in 14 healthcare centers of the department of Cochabamba suffered ADRs related to it. From all ADRs classified as moderate or severe (25% of the total ADRs registered), only about half of them (51.43%) were reported to the Bolivian Pharmacovigilance system [61]. This data illustrate the urgency of implementing policies to promote training in pharmacovigilance to all healthcare professionals, as well as strictly recommend the follow-up on drug monitoring and ADR reporting. Altogether, these features are fundamental to achieve strong and consolidated ADR reporting systems, which will improve patient safety, drug efficacy and adherence to treatment.

4. Patients’ comprehensive care: reference and counter-reference circuits

With less than 1% people treated [13,14], and an economic burden of \$7.19 billion per year and \$188.8 billion per lifetime [62], Chagas disease remains neglected despite the efforts performed by several institutions focused on the development and research [13]. Migratory flows have changed the epidemiology of the disease that is now emerging in some non-endemic countries [7]. During the last decades, collaboration and knowledge transfer between institutions from endemic (CEADES, Bolivia) and non-endemic countries (ISGlobal, Spain) have been strategic to build attention models for the Chagas disease patient. Such models could be scaled-up by national health systems in endemic and non-endemic countries in order to expand Chagas disease healthcare to people living in areas with limited access to health (e.g. rural areas in endemic countries) or to vulnerable populations (e.g. migrants in endemic and non-endemic countries).

4.1. The Platform for integral care of Chagas disease patients

The work made by this Platform in recent years have produced a quantitative and qualitative improvement in the healthcare provided to Chagas disease patients in Bolivia, but this improvement certainly needs to be strengthened. The

experience gained with the Platform in the country has shown that the implementation of specialized centers to manage people at risk of having Chagas disease is highly effective, both based on the percentage (and number) of people diagnosed with the infection, and amongst them, those who received and completed treatment [63]. This vertical strategy has been essential to design the attention model for patients with Chagas, making the medical assistance to these people look like a normalized and necessary action [63]. Nevertheless, the sustainability of such model ultimately depends on continuously securing external funds, which greatly complicates its expansion to larger geographical levels, like national coverage by the national health system (Figure 2).

4.2. Vertical-to-horizontal healthcare model transition

In order to have a higher impact in terms of diagnosis and treatment coverage, as well as to ensure the sustainability for the model of care of Chagas disease patients already installed, it is mandatory to search for a comprehensive horizontal strategy together with local higher level entities of the public health system. In fact, based on WHO recommendations, the strategy to include the Chagas disease attention roadmap as part of the regular activities of all healthcare levels seems to be the most appropriate approach [64].

Simplifying the vertical Chagas disease model of healthcare to more realistic protocols established together with the national health institutions has allowed the improvement of healthcare access for people at risk of having the disease living in remote areas of an endemic country [63]. Researchers at ISGlobal (authors of this review) have yet unpublished data which demonstrate that the health coverage, in terms of patients diagnosed and treated in the selected area in which the project has expanded its activity, was five times higher in the three years following the horizontal comprehensive care model than the number of people covered in the five previous years with the vertical strategy (Pinazo et al., unpublished).

So far, the outcome of the vertical-to-horizontal healthcare model transition highlight that it could be worthy to replicate and/or adapt it to other regions or countries. The first step would be to coordinate with local health authorities at different levels in order to design an appropriate strategy. For the

implementation of a healthcare model, the identification of interested health workers is a key issue. Even if it is simplified, a strategy to offer a comprehensive care for people at risk of suffering from Chagas disease should include: (a) specific training of health workers on the disease management; and (b) a strategy to increase the demand of the civil society, based on promotional and educational community activities. In this regard, the establishment of referral and counter-referral circuits tailored to each epidemiological and logistic situation is highly relevant, even in nearby areas.

4.3. Requirements for the expansion of the Chagas disease healthcare model

Referral and counter-referral circuits, in terms of patients and samples for diagnosis or any other test, should include different healthcare levels to cover different levels of complexity in terms of care. The specialized centers in which the model of care has been rehearsed in Bolivia are key towards organizing these circuits, as well as to act as reference centers for complicated cases and to accompany the doubts and the continuing education of health professionals from primary care centers. This is particularly important in health systems where there is often a fast renewal of healthcare personnel. Another crucial point to make sustainable a comprehensive horizontal strategy against Chagas disease is to promote an inter-sectorial collaboration with vector control authorities (promoters of house refurbishment, disinfection programs,...) and the educational system itself. Vector control interventions are fundamental to halt vector-dependent transmission and enable an enhanced drug control of the cases. Whereas educational activities to widen the population knowledge and perception of the disease, its impact, and treatment possibilities are crucial, because producing changes in beliefs, attitudes, and behaviors on both medical staff and patients still stand as one of the major challenges that must be faced when dealing with Chagas disease. All these measures have a role to play in order to consolidate the successful management of the disease.

On the other hand, lessons learned from the primary healthcare network have shown that it is mandatory to ensure the supervision of the circuits and surveillance the quality of




Figure 2. Comparison of the respective characteristics and requirements (in boxes) of the vertical and horizontal strategies to implement Chagas disease healthcare.

the process, tasks that should be carried out by the national health system responsible personnel in duty. Political engagement at this point is mandatory to contribute to a better control of the disease as a public health problem. In relation to this, it is important to respect the capability of local health institutions, agreeing with them timelines and a progressive increase of the number of people diagnosed and treated in order to answer adequately to people's demands. It must be noted that external factors like the poor availability of drugs for Chagas disease treatment have a sourly negative impact on any planning.

5. Patients treatment in relationship with vector control

Access to diagnosis and treatment of Chagas disease in areas with active vector transmission requires a multidisciplinary approach. It involves the participation of players from several areas of expertise and different government sectors, from vector control authorities to health service providers, including primary healthcare [65].

Following the advice from the PAHO, intergovernmental regional initiatives were created at the end of the twentieth century and beginning of the twenty-first century to establish supranational levels of action to bolster and monitor the implementation of activities to prevent, control, diagnose and treat Chagas disease in Latin America. These initiatives were started by Southern Cone countries in 1991, and then followed by Andean countries and Central American countries in 1997 and Amazonian countries in 2004 [66,67]. Despite these efforts, it is evident that in the region there was, and still is, a breach between the programs for vector control and the areas that are responsible for providing universal health care (including diagnosis and etiological treatment) [68].

It is important to consider that although policies related to the primary prevention of Chagas disease are defined at the national level, primary healthcare attention for the patient is the responsibility of the provincial/departmental or municipal/local entities [69]. Often times, these final effectors of national policies have little or no relation/communication with the national entity and are sometimes even unaware of the policies themselves. For example, suggestion of treatment of the infection by *T. cruzi* for postpartum women and their newborns, and the mandatory treatment for women of childbearing age and children under the age of one with Chagas disease that are in the national or supranational norms [32], make no specific mention of which protocols need to be applied with respect to vector surveillance in the houses of those patients living in endemic areas with active vector transmission. However, recent public health interventions have shown that activities related to access to diagnosis or treatment of the disease are usually implemented and promoted by those responsible for vector control programs [70]. Thus, without consideration of the need of appropriate structures and circuits (i.e. access to an adequate laboratory for diagnosis or presence of anti-trypanosomal drugs), which are not usually present in rural areas, one of the main actions needed is to establish and/or strengthen the link between vector control programs and the health system providers

[70]. Thereafter, following a stepwise approach, another action to accomplish would be to provide technical recommendations to establish criteria for categorizing the risk of vector transmission status in an endemic area. With that information available, it could be possible to explicitly detail under which conditions Chagas disease diagnosis and treatment has to be made mandatory in the area for the entire population or segments of it (i.e. women at childbearing age, newborns). Finally, a most desired third action would definitely be to integrate the procedures for disease diagnosis and treatment within the health system as a transversal program.

Nowadays there are already a few experiences that have been able to coordinate vector control actions together with diagnosis and treatment in a successful manner [71,72]. These could serve as proof-of-concept strategies for integral interventions to build on, improve and replicate. As an example, the experience of Fundación Mundo Sano, with direct and uninterrupted action in the field since 2002, is worth mentioning. Its integral program includes vector control and sanitary improvement of rural houses in the Department of General Taboada (Santiago del Estero, Argentina). In 2015, after 13 years of vector surveillance and control, Mundo Sano was able to install two doctors' offices dedicated to the diagnosis and treatment of Chagas disease together with local institutions, one in Añatuya City and another one in Colonia Dora. Since then, they have been struggling with the problems of having a mono-disease health service in a community that did not demand treatment. Despite the difficulties, after almost three years of implementation, the amount of people diagnosed and treated begun to increase. The work from these two Chagas disease-specific offices was integrated to the local hospital of Añatuya in 2018, thus reaching a higher amount of *T. cruzi*-infected individuals derived from obstetrics, gynecology and cardiology services in addition to those attending the offices from spontaneous demand. In the same line, the Platform for the Integral Care of Chagas disease Patients was settled in Bolivia in 2009. Initially, in the province of Cochabamba in the center of the country, the Platform now works also in municipalities of the provinces of Chuquisaca and Tarija [63]. Each experience, proposal or pilot study must be evaluated objectively in order to improve and multiply its impact, avoiding a future with a new inequality: one were those affected by the disease will have access to health depending on whether they live in an endemic or non-endemic area.

6. The role of patients' associations

Similarly to what happens with other NTDs programs to promote scaling up of healthcare interventions, strategies towards the control of Chagas disease often confront with structural weaknesses of the health systems in which they aim to be integrated [73–76]. Therefore, more effective strategies to strengthen those health systems are required to ensure a sustainable integration of the required health innovations within them. Importantly, these strategies need to incorporate the patients' perspective in order to overcome key access barriers [13,14,75]. Barriers that nowadays still hinder the access to diagnosis and treatment, barriers impeding a better health care.

In recent years, several associations of Chagas disease patients have emerged and joined in a Federation of Associations whose purposes are: (i) to increase the visibility of the disease at all levels as well as of its overwhelming impact in the patients' health status; and (ii) to promote a more active role of the people affected by the disease in the decision-making processes. But these associations face many difficulties (dispersion of objectives, multiplicity of voices with different requirements, little real mobilization in many countries, and lack of resources) to achieve their objective of having an effective role in the health policies makings of their countries.

The WHO global strategy on integral health services centered on people could be a way through which these associations can play an important practical role [77]. In fact one of the goals of such program is to empower individuals, families, and communities by including in it some well-known activities led by patients such as community education, groups of patients for mutual support, expert patients to engage and help others, etc. [77]. In addition, this WHO program goes beyond a single disease and has the virtue of encompassing other actors with decisive roles in health systems performance, like governmental policy-makers, municipalities, donors, and providers.

Overall, the strategy is thus envisaged to allow the community and patients to actively participate in the decision-making process, together with other involved actors, in issues regarding their health. By doing so, they also play a role on the way the health system is organized, for instance ensuring that community and primary healthcare are prioritized. Therefore, patients associations should look after the implementation and compliance with this WHO strategy as it underlies the activities they are already taking on.

7. The R&D agenda: clinical trials for new drugs or new strategies of treatment with current drugs

7.1. Results from recently completed trials

Upon the questioned efficacy of currently available therapies (BNZ and NFX) against the chronic symptomatic stage of the disease, clinical testing of new drugs and/or of new regimens of BNZ and NFX is being pursued. Nonetheless, some major obstacles are in the way to getting more adequate treatments, including the poor understanding of the infection

pathophysiology leading to the disease clinical progression, and the lack of biomarkers to determine prognosis and cure (see review by Pinazo et al. [19]). Particularly the latter hinders the follow-up of treated patients both in the daily clinic and in clinical trials. At present, an absence of molecular amplification of *T. cruzi* DNA from periphery blood is used as surrogate of 'treatment success'. But this approach is far from optimal, especially at the chronic stage of the disease when the parasitemia is low and intermittent. A negative result obtained at a determined time point does not exclude the possibility that a positive one will be obtained in the next visit. A false-negative PCR, i.e. a negative PCR result ('treatment success' event) in the patient follow up is then less informative than a positive determination, as this one will indeed define a case of treatment failure.

Despite this limitation, several clinical trials have been completed in the last years, and there are several more currently ongoing. This advance represents a major shift in the research landscape of this historically forgotten NTD. The vast majority of the performed trials have been Phase 2 randomized, multi-centric, double-blinded, efficacy and safety studies to evaluate oral dosage schemes for the treatment of adult patients at indeterminate (asymptomatic) chronic stage (see Table 1). Amongst them, CHAGASAZOL [78], STOP CHAGAS [79] and E1224 [31] have evaluated for the first time two triazole anti-fungal drugs (posaconazole (POS), and the ravuconazole precursor E1224) for their anti-*T. cruzi* properties. In addition, the BENEFIT trial that evaluated the use of BNZ for chronic stage treatment must also be highlighted as it has been the largest Phase 3 Chagas disease trial performed so far [47].

CHAGASAZOL and E1224 trials entailed a direct comparison of POS and E1224 monotherapy at a high and a low dose to a BNZ standard dosage group (5 mg/kg/day orally divided in two daily doses for 60 days) [31,78]. In addition to monotherapy branches, STOP CHAGAS trial also included a study group that received POS and BNZ as combined therapy [79]. In the latter, treatment success was defined as a negative PCR value at the day 180 follow-up visit [79], whereas parasitological cure in CHAGASAZOL was determined by a negative PCR result at 12 months follow-up [78]. The most stringent success criteria was that of E1224 trial, which involved serial negative PCR results (3 negative PCR results from 3 samples collected over 7 days) at 65 days after the end of treatment and a further negative PCR outcome at 12 months follow-up [31].

Table 1. List of the most relevant anti-*T. cruzi* clinical trials recently completed.

Name	NCT number ^a	Drug tested	No. of patients	Outcome ^b	Ref.
CHAGASAZOL	01162967	POS	78	>80% (POS) 38.4% (BNZ)	[78]
STOP CHAGAS	01377480	POS POS-BNZ	120	>86% (POS) 14.3% (BNZ) 20% (POS+BNZ)	[79]
E1224	01489228	E1224	231	≥81% (E1224) 18% (BNZ)	[31]
BENEFIT	00123916	BNZ	2854 (1896) ^c	44.6% (BNZ) ^d	[47]

^aClinical trial identification number (check it out at <https://clinicaltrials.gov>).

^bStudy outcome shown as treatment failure measured by PCR; STOP CHAGAS entry also includes the failure rate in the POS+BNZ group.

^{c,d}Number in parenthesis stands for the number of patients with a PCR result at baseline of which 60.5% were positive. The outcome shown indicates the % of initially PCR positive patients who were reported PCR positive again at two years.

Although both POS and E1224 drugs showed good safety and efficacy profiles at end of treatment in the three studies, the suppressive effect on parasite clearance after 12 months was much reduced in comparison to BNZ, which showed early and sustained efficacy until 12 months of follow-up (Table 1). Thus, neither POS nor E1224 were as good as BNZ and could not substitute it as monotherapies.

In the BENEFIT trial, the treatment response was evaluated in a sub-group of 1,896 subjects who had PCR results at baseline (60.5% of them were positive) by PCR conversion at the end of treatment, and at two and five years post-treatment [47]. Being a large multi-national study, the PCR conversion rates varied geographically with Bolivia and Argentina showing the best results, though it must be noticed that such conversion did not correlate with clinical outcome [47]. BENEFIT was devised to study whether BNZ administration to patients at the chronic stage of the disease would widely have a clinical benefit for them [22,47]. Sadly, its conclusions, far from reassuring the role of BNZ turned out to be a setback, as they suggested not-to treat patients with advanced cardiac disease [47]. As it has been criticized elsewhere, this devastating conclusion drains from the fact that many subjects with advanced cardiac involvement were enrolled in the study [3,22]. Despite its negative outcome due to a rather questionable study protocol design [22], the BENEFIT trial involved ample cooperation between multiple study sites opening the door to the performance of multi-national Phase 3 Chagas disease trials in South America [47].

7.2. Ongoing clinical trials of anti-*T. cruzi* drugs

There are now some active and/or ongoing clinical trials. Some test alternative BNZ dosing regimens to reduce exposure, improve tolerability and maintain efficacy as described elsewhere [52], based also on the description of BNZ pharmacokinetics (PK) in Chagas disease adult patients [80]. In others, the evaluation of NFX has gained prominence under the promotion of Bayer, NFX producer. The use of fexinidazole, a nitroimidazole drug like BNZ that is being trialed for human African trypanosomiasis and leishmaniasis (respectively caused by *T. cruzi* closely related Kinetoplastid parasites *T. brucei gambiense* and *T. brucei rhodensiense*, and by *Leishmania* spp.), and the antiarrhythmic drug amiodarone are also being clinically assessed for the first time against *T. cruzi* based on their anti-parasitic capacities [81,82]. These ongoing trials range from smaller Phase 1 to larger Phase 2

and 3 efficacy studies. There are: (1) a Phase 1 safety, tolerability and bioavailability assessment of new NFX tablets and another Phase 1 study to determine NFX PK in relation to dietary habits; (2) a Phase 2 study to evaluate different BNZ regimens (MULTIBENZ); (3) another Phase 2 study to evaluate reduced and intermittent BNZ regimens, either given alone or in combination with E1224 (BENDITA); (4) two more Phase 2 studies evaluating fexinidazole to, respectively, determine dosing regimens and the minimal efficacious and safety dose; (5) a Phase 2–3 trial to compare safety and efficacy of NFX and BNZ (EQUITY); (6) a Phase 3 study to assess amiodarone, a commonly used antiarrhythmic with selective anti-*T. cruzi* properties, administered over 6 months to individuals with mild-to-moderate Chagas cardiomyopathy (ATTACH); (7) a Phase 3 study of a pediatric formulation of NFX (CHICO); and (8) a very recently added Phase 3 study to evaluate a short dose of BNZ in child-bearing age women (BETTY) (Table 2).

All Phase 2 or above trials in Table 2 but CHICO involve the evaluation of drugs in chronically infected adult patients, and the measurement of treatment success will rely on molecular detection of the parasite DNA. In contrast, in CHICO, designed to assess NFX performance in Chagas disease infant population, the way to measure cure is seroconversion a year after treatment because this is much easier to timely occur in children than in adults and its readout is less ambiguous than the PCR output. All these studies are currently in the recruiting stage, except FEXI NCT02498782 and CHICO which are active but not recruiting, and BETTY that is not yet recruiting (<https://clinicaltrials.gov>). Regarding the latter, the benefits of treating *T. cruzi*-infected women before pregnancy have been described by several smaller studies [23–26]. Hopefully, BETTY's outcome will serve to enforce treatment administration to all child-bearing age women as soon as possible.

8. Conclusion

Increasing the awareness on the prevalence and health impact of Chagas disease among patients, health practitioners, and political health authorities may eventually translate to enhance population-based diagnostic screening and treatment interventions. The tools needed to facilitate this activity are being tested currently in the field and incorporate more practical and point-of-care diagnostics, new drugs regimens, and the standardization of daily clinical care routines. In

Table 2. List of currently ongoing clinical trials of anti-*T. cruzi* drugs.

Name	NCT number ^a	Drug tested	Study type	No. of patients (estimated)	Promoter
-	03350295	NFX	Phase 1	48	Bayer
-	03334838	NFX	Phase 1	36	Bayer
MULTIBENZ	03191162	BNZ	Phase 2	240	Hospital Vall d'Hebron (Spain)
BENDITA	03378661	BNZ and E1224	Phase 2	210	DNDi
-	02498782	FEXI	Phase 2	140	DNDi
-	03587766			45	
EQUITY	02369978	NFX and BNZ	Phase 2–3	500	Autonomous University of Bucaramanga (Colombia)
ATTACH	03193749	AMD	Phase 3	200	Fundación Cardioinfantil – Instituto de Cardiología de Bogotá (Colombia)
CHICO	02625974	NFX	Phase 3	330	Bayer
BETTY	03672487	BNZ	Phase 3	600	Tulane University (USA)

^aClinical trial identification number (check it out at <https://clinicaltrials.gov>).

addition, efforts to obtain biomarkers of disease prognosis and early assessment of treatment are also being pursued and will probably yield results soon.

Upon failure of azoles, the majority of presently ongoing Chagas disease clinical trials either evaluate alternative regimens of current drugs or other chemical entities distinct from azoles (e.g. fexinidazole, amiodarone) with the aim to identify dosages with lower toxicity and at least equal efficacies compared to present chemotherapy with either benznidazole or nifurtimox. There is certain optimism on that a new treatment for Chagas disease can be scheduled in the next few years. Further complementing the new anti-parasitic drugs is a new therapeutic biologic, a vaccine, now advancing to the clinic. However, access to these new drugs and innovations will require enhanced policies and advocacy activities. In parallel, it will be essential to shape and disseminate pharmacovigilance protocols so that the performance of the drug can be closely monitored, and patients' and healthcare providers' confidence on these therapies is promoted and maintained.

The functional deployment of counter-reference circuits fully integrated in the national health services will be required to scale up the attention to Chagas disease patients. In this regards, improved coordination between vector control authorities and sanitary authorities needs strengthening in those regions with active vector transmission of the infection. Widespread access to diagnosis and treatment will not yield the desired outcome unless chances to get re-infected are minimized or eliminated. This approach also requires maintaining blood screening and programs to stop congenital transmission. An improved maternal diagnosis and treatment protocol would in itself reduce congenital transmission.

Despite recently achieved advancements, Chagas disease management and control is still a huge challenge. Therefore, to succeed in this matter it will be paramount the continued involvement of key actors, including patients associations, health authorities at regional and national levels, governmental and non-governmental institutions, basic and clinical researchers, and of course financial partners.

9. Expert opinion

A huge drawback in the management of Chagas disease has traditionally been the lack of awareness of the disease and its impact by both health professionals and the patients themselves, as well as by governmental institutions with the power to dictate health policies. However, Chagas disease awareness is gradually increasing, so that efforts to combat this neglected tropical disease now need to shift in order to address its often insidious onset and silent clinical progression. These features currently complicate the access to timely diagnosis and treatment, which is also ballasted by the very limited resources available for research and development of improved treatment and disease prevention methodologies.

After so many years of neglecting Chagas disease, new efforts at R&D have the potential for high returns on investment. However, the R&D needs for Chagas disease are pervasive and span requirements for both basic and applied

research, as well as new drugs, diagnostics, and vaccines. With the ultimate goal of controlling the disease in endemic and non-endemic regions, the consequences of widening our understanding on Chagas disease and the pathogen that causes it will have an impact on the lives of millions of people. For instance, research on parasite–host interactions is needed to fully comprehend the pathogenic processes that lead to the life-threatening symptomatology characteristic of chronic *T. cruzi* infections. Furthermore, considering that in the absence of treatment ~30% of those chronically infected will develop cardiac and/or digestive tract disruptions, studies on both parasite and host genomics (and other omics) are required to determine the key factors leading to the development of pathogenesis. Deeper understanding of the parasite biology and of its interactions with the host is fundamental for the discovery of safer drugs or vaccines. Another challenge is the dearth of public policies and advocacy that so far has mostly failed to attract requisite funding.

Currently, the most urgent needs include an expansion in clinical studies to test an enlarged portfolio of new drugs, together with improved biomarkers to monitor disease progress. There is also urgency for inexpensive and accessible point-of-care diagnostics, especially for mass screenings as well as for the early assessment of treatment responses. Their availability will widen access to treatment because they would introduce a more accurate picture of the disease epidemiology, as well as the ability to acknowledge cure upon treatment.

Funding

This work is supported by the Departament d'Universitats i Recerca de la Generalitat de Catalunya, Spain [AGAUR; 2017SGR00924] and by the Instituto de Salud Carlos III RICET Network for Cooperative Research in Tropical Diseases [ISCIII; RD12/0018/0010].

Declaration of interest

J Alonso-Padilla holds a Juan de la Cierva – Incorporación contract from the Spanish Science Ministry and is member of the NHEPACHA network. J Gascon is Director of the Chagas Initiative at ISGLOBAL and Head of the Tropical Medicine Service at Hospital Clinic (Barcelona, Spain). J Gascon currently coordinates NHEPACHA network and is member of the scientific committees of CEADES (Bolivia) and ISGLOBAL. M J Pinazo and S Sosa-Estani are members of the NHEPACHA scientific network. M E Botazzi and P J Hotez are patent-holders and lead investigators of a program for the development of a therapeutic Chagas disease vaccine. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

ORCID

Julio Alonso-Padilla  <http://orcid.org/0000-0003-4466-7969>

Peter Jay Hotez  <http://orcid.org/0000-0001-8770-1042>

References

Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers.

- Pérez-Molina JA, Molina I. Chagas disease. *Lancet*. 2018;391:82–94.
- Naghavi M, Abajobir AA, Abbafati C, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017;390:1151–1210.
- Pecoul B, Batista C, Stobbaerts E, et al. The BENEFIT trial: where do we go from here? *PLoS Negl Trop Dis*. 2016;10:e0004343.
- Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017;390:1211–1259.
- Manne-Goehler J, Umeh CA, Montgomery SP, et al. Estimating the burden of Chagas disease in the United States. *PLoS Negl Trop Dis*. 2016;10:e0005033.
- WHO. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. *Weekly Epidemiological Rec*. 2015;90(5):33–43. Geneva (Switzerland).
- Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. *Acta Trop*. 2010;115:22–27.
- Requena-Méndez A, Aldasoro E, de Lazzari E, et al. Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis. *PLoS Negl Trop Dis*. 2015;9:e0003540.
- Food and drug administration news release: FDA approves first US treatment for Chagas disease. Silver Spring, MD; 2017. [cited 2018 Oct 6]. Available from: <https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm573942.htm>
- Cruz-Reyes A, Pickering-López JM. Chagas disease in Mexico: an analysis of geographical distribution during the past 76 years – a review. *Mem Inst Oswaldo Cruz*. 2006;101:345–354.
- Manne JM, Snively CS, Ramsey JM, et al. Barriers to treatment access for Chagas disease in Mexico. *PLoS Negl Trop Dis*. 2013;7:e2488.
- Manne-Goehler J, Reich MR, Wirtz VJ. Access to care for Chagas disease in the United States: a health systems analysis. *Am J Trop Med Hyg*. 2015;93:108–113.
- Moriana S, Ortiz G, Fanjul G. Rompiendo el silencio. Una oportunidad para los pacientes de Chagas. [Breaking the silence. An opportunity for Chagas disease patients]. Barcelona: Coalición Global de la Enfermedad de Chagas; 2016.
- WHO media centre: Chagas disease (American trypanosomiasis) fact sheet; 2018. [cited 2018 Oct 6]. Available from: <http://www.who.int/mediacentre/factsheets/fs340/en/>
- Bahia MT, Nascimento AFS, Mazzetti AL, et al. Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease. *Antimicrob Agents Chemother*. 2014;58:4362–4370.
- Beaumier CM, Gillespie PM, Strych U, et al. Status of vaccine research and development of vaccines for Chagas disease. *Vaccine*. 2016;34:2996–3000.
- Jones K, Versteeg L, Damania A, et al. Vaccine-linked chemotherapy improves benznidazole efficacy for acute Chagas disease. *Infect Immun*. 2018;86:pil e00876–17.
 - Work where co-administration of an immunotherapeutic vaccine (recombinant parasite protein Tc24 adjuvanted by E6020) and BNZ was tested in an experimental mouse model of *T. cruzi* infection to reduce the dose of the latter in search of improved tolerability while keeping efficacy.**
- Picado A, Angheben A, Marchiol A, et al. Development of diagnostics for Chagas disease: where should we put our limited resources? *PLoS Negl Trop Dis*. 2017;11:e0005148.
- Pinazo MJ, Thomas MC, Bua J, et al. Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. *Expert Rev Anti Infect Ther*. 2014;12:479–496.
 - Extensive review by Pinazo and co-workers on the status of biological markers to address treatment response of Chagas disease.**
- Alonso-Padilla J, Gallego M, Schijman AG, et al. Molecular diagnostics for Chagas disease: up to date and novel methodologies. *Expert Rev Mol Diagn*. 2017;17:699–710.
- Zingales B. *Trypanosoma cruzi* genetic diversity: something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. *Acta Trop*. 2018;184:38–52.
- Rassi A, Marin-Neto JA, Rassi A. Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the benznidazole evaluation for interrupting trypanosomiasis (BENEFIT) trial. *Mem Inst Oswaldo Cruz*. 2017;112:224–235.
 - Paper that discusses on BENEFIT trial limitations and implications written by researchers that participated in the outlining of the first protocol of this controversial trial.**
- Álvarez MG, Vigliano C, Lococo B, et al. Prevention of congenital Chagas disease by benznidazole treatment in reproductive-age women. An observational study. *Acta Trop*. 2017;174:149–152.
- Fabbro DL, Danesi E, Olivera V, et al. Trypanocidal treatment of women infected with *Trypanosoma cruzi* and its effect on preventing congenital Chagas. *PLoS Negl Trop Dis*. 2014;8:e3312.
 - Observational study of a cohort of *T. cruzi*-infected mothers-to-be who were treated or not with BNZ before pregnancy. It showed that treatment was efficient to prevent congenital transmission plus it protected the chronically infected women from clinically evolving the disease.**
- Moscattelli G, Moroni S, García-Bournissen F, et al. Prevention of congenital Chagas through treatment of girls and women of childbearing age. *Mem Inst Oswaldo Cruz*. 2015;110:507–509.
- Murcia L, Simón M, Carrilero B, et al. Treatment of infected women of childbearing age prevents congenital *Trypanosoma cruzi* infection by eliminating the parasitemia detected by PCR. *J Infect Dis*. 2017;215:1452–1458.
- Requena-Méndez A, Bussion S, Aldasoro E, et al. Cost-effectiveness of Chagas disease screening in Latin American migrants at primary health-care centres in Europe: a markov model analysis. *Lancet Glob Health*. 2017;5:e439–e447.
- Ramsey JM, Elizondo-Cano M, Sanchez-González G, et al. Opportunity cost for early treatment of Chagas disease in Mexico. *PLoS Negl Trop Dis*. 2014;8:e2776.
- Sicuri E, Muñoz J, Pinazo MJ, et al. Economic evaluation of Chagas disease screening of pregnant Latin American women and of their infants in a non endemic area. *Acta Trop*. 2011;118:110–117.
- Stillwaggon E, Perez-Zetune V, Bialek SR, et al. Congenital Chagas disease in the United States: cost savings through maternal screening. *Am J Trop Med Hyg*. 2018;98:1733–1742.
- Torrico F, Gascon J, Ortiz L, et al. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. *Lancet Infect Dis*. 2018;18:419–430.
- Carlier Y, Sosa-Estani S, Luquetti AO, et al. Congenital Chagas disease: an update. *Mem Inst Oswaldo Cruz*. 2015;110:363–368.
- Besuschio SA, Llano Murcia M, Benatar AF, et al. Analytical sensitivity and specificity of a loop-mediated isothermal amplification (LAMP) kit prototype for detection of *Trypanosoma cruzi* DNA in human blood samples. *PLoS Negl Trop Dis*. 2017;11:e0005779.
 - Analytical description of the *T. cruzi* LAMP prototype in terms of sensitivity, specificity, inclusivity, selectivity, and limits of detection and quantification of various parasite genotypes. LAMP performance was also compared with that of qPCR over a set of clinical samples.**
- Rivero R, Bisio M, Velázquez EB, et al. Rapid detection of *Trypanosoma cruzi* by colorimetric loop-mediated isothermal amplification (LAMP): a potential novel tool for the detection of congenital Chagas infection. *Diagn Microbiol Infect Dis*. 2017;89:26–28.
- Notomi T, Okayama H, Masubuchi H, et al. Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res*. 2000;28:E63.
 - Description of the development of the fast method to detect DNA at high specificity and efficiency under isothermal conditions known as loop-mediated isothermal amplification (LAMP).**

36. Jimenez-Coello M, Shelite T, Castellanos-Gonzalez A, et al. Efficacy of recombinase polymerase amplification to diagnose *Trypanosoma cruzi* infection in dogs with cardiac alterations from an endemic area of Mexico. *Vector-Borne Zoonotic Dis.* 2018;8:417–423.
37. Mondal D, Ghosh P, Khan MA, et al. Mobile suitcase laboratory for rapid detection of Leishmania donovani using recombinase polymerase amplification assay. *Parasites Vectors.* 2016;9:281.
38. El Wahed AA, Patel P, Faye O, et al. Recombinase polymerase amplification assay for rapid diagnostics of dengue infection. *PLoS One.* 2015;10:e0129682.
39. Médecins Sans Frontières. Campaign for access to essential medicines. International meeting: new diagnostic tests are urgently needed to treat patients with Chagas disease. *Rev Soc Bras Med Trop.* 2008;41:315–319.
40. Sánchez-Camargo CL, Albajar-Viñas P, Wilkins PP, et al. Comparative evaluation of 11 commercialized rapid diagnostic tests for detecting *Trypanosoma cruzi* antibodies in serum banks in areas of endemicity and nonendemicity. *J Clin Microbiol.* 2014;52:2506–2512.
41. Egüez KE, Alonso-Padilla J, Terán C, et al. Rapid diagnostic tests duo as alternative to conventional serological assays for conclusive Chagas disease diagnosis. *PLoS Negl Trop Dis.* 2017;11:e0005501.
- **Proof-of-concept study to demonstrate that the use of two RDTs could potentially substitute currently followed conventional serology algorithm of chronic Chagas disease diagnosis.**
42. Roddy P, Goiri J, Flevaud L, et al. Field evaluation of a rapid immunochromatographic assay for detection of *Trypanosoma cruzi* infection by use of whole blood. *J Clin Microbiol.* 2008;46:2022–2027.
43. Shah V, Ferrufino L, Gilman RH, et al. Field evaluation of the InBios Chagas detect plus rapid test in serum and whole-blood specimens in Bolivia. *Clin Vaccine Immunol.* 2014;21:1645–1649.
44. Verani JR, Seitz A, Gilman RH, et al. Geographic variation in the sensitivity of recombinant antigen-based rapid tests for chronic *Trypanosoma cruzi* infection. *Am J Trop Med Hyg.* 2009;80:410–415.
- **Field study pointing out that the sensitivity and specificity of RDTs may depend on the geographical region studied due to factors such as the circulating *T. cruzi* strains and their prevalence level.**
45. Viotti R, De Noya BA, Araujo-Jorge T, et al. Towards a paradigm shift in the treatment of chronic Chagas disease. *Antimicrob Agents Chemother.* 2014;58:635–639.
46. Cardoso CS, Ribeiro ALP, Oliveira CDL, et al. Beneficial effects of benznidazole in Chagas disease: NIH SaMi-trop cohort study. *PLoS Negl Trop Dis.* 2018;12:e0006814.
- **Large cohort study that demonstrates the beneficial effects of the administration of BNZ in the early phases of chronic Chagas disease, in terms of lower parasitemia levels, lower prevalence of markers of severe cardiomyopathy, and lower mortality in comparison to a non-treated group.**
47. Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. *N Engl J Med.* 2015;373:1295–1306.
- **Publication describing the performance and main outcome of the Phase III BNZ clinical trial BENEFIT.**
48. Jackson Y, Alirol E, Getaz L, et al. Tolerance and safety of nifurtimox in patients with chronic Chagas disease. *Clin Infect Dis.* 2010;51:e69–75.
49. Pinazo MJ, Muñoz J, Posada E, et al. Tolerance of benznidazole in treatment of Chagas' disease in adults. *Antimicrob Agents Chemother.* 2010;54:4896–4899.
50. Aldasoro E, Posada E, Requena-Méndez A, et al. What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment. *J Antimicrob Chemother.* 2018;73:1060–1067.
51. Filardi LS, Brener Z. Susceptibility and natural resistance of *Trypanosoma cruzi* strains to drugs used clinically in Chagas disease. *Trans R Soc Trop Med Hyg.* 1987;81:755–759.
52. Álvarez MG, Hernández Y, Bertocchi G, et al. New scheme of intermittent benznidazole administration in patients chronically infected with *Trypanosoma cruzi*: a pilot short-term follow-up study with adult patients. *Antimicrob Agents Chemother.* 2016;60:833–837.
- **Pilot clinical study that showed safety and efficacy of an intermittent schedule of BNZ and this way settled the basis for currently ongoing larger trials with alternative dosages of the drug.**
53. Bustamante JM, Craft JM, Crowe BD, et al. New, combined, and reduced dosing treatment protocols cure *Trypanosoma cruzi* infection in mice. *J Infect Dis.* 2014;209:150–162.
54. WHO. Annex 119th WHO Model List of Essential Medicines. Geneva, Switzerland: World Health Organization; 2015 Apr.
55. Médecins sans frontières press release: shortage of benznidazole leaves Chagas patients without treatment. Barcelona, Asunción, La Paz, Rio de Janeiro. 2011 Oct 5. [cited 2018 Oct 6]. Available from: <http://www.msf.org/en/article/shortage-benznidazole-leaves-chagas-patients-without-treatment>
56. Dias JC, Coura JR, Yasuda MA. The present situation, challenges, and perspectives regarding the production and utilization of effective drugs against human Chagas disease. *Rev Soc Bras Med Trop.* 2014;47:123–125.
57. Jannin J, Villa L. An overview of Chagas disease treatment. *Mem Inst Oswaldo Cruz.* 2007;102(Suppl 1):95–97.
58. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *Lancet.* 2000;356:1255–1259.
59. Working Group on Pharmacovigilance; PANDRH Technical Document No 5. Pan American network on drug regulatory harmonization, good pharmacovigilance practices for the Americas. Washington, DC: Pan American Health Organization / World Health Organization (PAHO/WHO); 2011.
60. González JC, Arango VE, Einarson TR. Contribution of Latin America to pharmacovigilance. *Ann Pharmacother.* 2006;40:1394–1399.
61. Cortes-Serra N, Saravia R, Grágeda RM, et al. Strengthening Bolivian pharmacovigilance system: new therapeutic strategies to improve health of Chagas disease and tuberculosis patients. *Forthcoming.*
62. Lee BY, Bacon KM, Bottazzi ME, et al. Global economic burden of Chagas disease: a computational simulation model. *Lancet Infect Dis.* 2013;13:342–348.
63. Pinazo MJ, Pinto J, Ortiz L, et al. A strategy for scaling up access to comprehensive care in adults with Chagas disease in endemic countries: the Bolivian Chagas Platform. *PLoS Negl Trop Dis.* 2017;11:e0005770.
64. WHO Expert Committee. Control of Chagas disease. *World Health Organ Tech Rep Ser.* 2002;905:i-vi, 1–109. back cover.
65. Pinazo MJ, Gascon J. The importance of the multidisciplinary approach to deal with the new epidemiological scenario of Chagas disease (global health). *Acta Trop.* 2015;151:16–20.
66. [Various authors] El control de la enfermedad de Chagas en los países del Cono Sur de América: historia de una iniciativa internacional 1991/2001. [The control of Chagas disease in America's Southern Cone countries: history of an international initiative]. Pan American Health Organization / World Health Organization (PAHO/WHO); Washington D.C. (USA); 2002.
67. WHO. 63ª Asamblea Mundial de la Salud A63/17 [World health assembly]. Enfermedad de Chagas: Control y eliminación [Chagas disease: control and elimination]. 2010 May 17–21; Geneva, Switzerland: World Health Organization.
68. Gürtler RE. Sustainability of vector control strategies in the Gran Chaco Region: current challenges and possible approaches. *Mem Inst Oswaldo Cruz.* 2009;104(Suppl 1):52–59.
69. Villa L, Morote S, Bernal O, et al. Access to diagnosis and treatment of Chagas disease/infection in endemic and non-endemic countries in the XXI century. *Mem Inst Oswaldo Cruz.* 2007;102(Suppl 1):87–94.
70. Gürtler RE, Kitron U, Cecere MC, et al. Sustainable vector control and management of Chagas disease in the Gran Chaco, Argentina. *Proc Natl Acad Sci U S A.* 2007;104:16194–16199.
- **Vector-control study in rural communities of Northern Argentina that showed how relevant are the continuous supervision of the desinfestation, the engagement of local communities, and the improvement of housing in order to efficiently cut down vector-mediated transmission.**
71. Sartor P, Colaizzi I, Cardinal MV, et al. Improving access to Chagas disease diagnosis and etiologic treatment in remote rural

- communities of the Argentine Chaco through strengthened primary health care and broad social participation. *PLoS Negl Trop Dis.* **2017**;11:e0005336.
72. Yun O, Lima MA, Ellman T, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-Year experience of *médecins sans frontières*. *PLoS Negl Trop Dis.* **2009**;3:e488.
 73. Marchal B, Van Dormael M, Pirard M, et al. Neglected tropical disease (NTD) control in health systems: the interface between programmes and general health services. *Acta Trop.* **2011**;120 (Suppl 1):S177–S185.
 74. Ortu G, Williams O. Neglected tropical diseases: exploring long term practical approaches to achieve sustainable disease elimination and beyond. *Infect Dis Poverty.* **2017**;6:147.
 75. Gyapong JO, Gyapong M, Yellu N, et al. Integration of control of neglected tropical diseases into health-care systems: challenges and opportunities. *Lancet.* **2010**;375:160–165.
 76. Cucunubá ZM, Manne-Goehler JM, Díaz D, et al. How universal is coverage and access to diagnosis and treatment for Chagas disease in Colombia? A health systems analysis. *Soc Sci Med.* **2017**;175:187–198.
 77. World Health Organization. **2015**. WHO global strategy on people-centred and integrated health services: interim report. Available from: <http://www.who.int/service-delivery-safety/areas/people-centred-care/global-strategy/en/>
 78. Molina I, Gómez I, Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. *N Engl J Med.* **2014**;370:1899–1908.
 - **First published clinical trial with a drug different from BNZ and NFX, where the anti-*T. cruzi* properties of azole derivative posaconazole were evaluated. Despite it was preceded by remarkable pre-clinical results with (not very translatable) animal models of *T. cruzi* infection, the outcome of the trial was very discouraging.**
 79. Morillo CA, Waskin H, Sosa-Estani S, et al. Benznidazole and posaconazole in eliminating parasites in asymptomatic *T. cruzi* carriers: the STOP-CHAGAS trial. *J Am Coll Cardiol.* **2017**;69:939–947.
 80. Soy D, Aldasoro E, Guerrero L, et al. Population pharmacokinetics of benznidazole in adult patients with Chagas disease. *Antimicrob Agents Chemother.* **2015**;59:3342–3349.
 81. Bahia MT, de Andrade IM, Martins TA, et al. Fexinidazole: a potential new drug candidate for Chagas disease. *PLoS Negl Trop Dis.* **2012**;6:e1870.
 82. Adesse D, Azzam EM, De Meirelles MNL, et al. Amiodarone inhibits *Trypanosoma cruzi* infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro. *Antimicrob Agents Chemother.* **2011**;55:203–210.